Rheum Now shares Day 3 highlights from #ACR20. https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh

• https://bit.ly/2IhSKj0

RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

• Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of R…

Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q

• https://twitter.com/UNMC_Rheum/status/1325840359411343362

SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.co/WBaWN9d8vs

• Comparison of Two Rituximab Regimens for Induction of Remission in Antineutroph…

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @RheumNow @ElaineHusniMD https://t.co/MW0fOAeK09

Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/s6fKEW8czc

Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/jyjRD5aadN

Rituximab in AAV: how to dose? Should we be giving: - 'haem dosing': 375mg/m2 x4 doses - 'RA dosing': 1000mg x2 doses Systematic review says: no difference Reassuring given the variation in practice in real life! #ACR20 ABST2048 @RheumNow https://t.co/Jf4Ue6HRRL

Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/I0feVuZ8iy

Anakinra in #Stills disease - Double blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at week 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90 @RheumNow #ACR20 ABS#1633 #ACRbest https://t.co/9E4vm7WzhP

Wonder if you can predict which pts you can successfully taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26) & low Doppler serum score for 24 jts predicted successful discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. #ACR20 @RheumNow https://t.co/CbJTguxaoa

Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20 https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc

• https://bit.ly/353aM15

#FDA updates #ACR20 @rheumnow labeling/warning changes: belimumab- mortality removed abatacept - angioedema added baricitinib -hypersensitivity rxn added gabapentin & pregabalin - respiratory depression added

Dr Sanchez-Bilbao reports a study of 30 patients with LV GCA. Despite clinical remission with tocilizumab ongoing vascular inflammatory activity identified by PET in 70%. Significant implications for risk of tocilizumab withdrawal. @rheumnow #ACR20 Abstr#1921 https://t.co/f1isidSypn